Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema

References

• Zuraw BL. Clinical practice. Hereditary angioedema. N. Engl. J. Med.359(10), 1027–1036 (2008).
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin. Immunol.6(1), 24 (2010).
   PubMedGoogle Scholar
• Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus. Apher. Sci.29, 235–238 (2003).
   PubMed Web of Science ®Google Scholar
• Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin. Proc.75(4), 349–354 (2000).
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am. J. Med.119(3), 267–274 (2006).
   PubMed Web of Science ®Google Scholar
• Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol.139(3), 379–394 (2005).
   PubMed Web of Science ®Google Scholar
• Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc.31(5), 407–414 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann. Allergy Asthma Immunol.104(4), 314–320 (2010).
   PubMed Web of Science ®Google Scholar
• Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science148, 957–958 (1965).
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygoren-Pursun E, Binkley KE et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol.114(Suppl. 3), S51–S131 (2004).
   PubMed Web of Science ®Google Scholar
• Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy33, 330–341 (1962).
   PubMedGoogle Scholar
• Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema, absence of serum inhibitor of C1-esterase. Am. J. Med.35, 37–44 (1963).
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann. Allergy Asthma Immunol.104(3), 193–204 (2010).
   PubMed Web of Science ®Google Scholar
• Craig T, Riedl M, Dykewicz MS et al. When is prophylaxis for hereditary angioedema necessary? Ann. Allergy Asthma Immunol.102(5), 366–372 (2009).
   PubMed Web of Science ®Google Scholar
• Zuraw B, Busse P, White M, Jacobs J, Lumry W, Baker J. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N. Engl. J. Med.363(6), 513–522 (2010).
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J. Allergy Clin. Immunol.124(4), 801–808 (2009).
   PubMed Web of Science ®Google Scholar
• Berinert®, package insert. CSL Behring LLC, Kankakee, IL, USA (2011).
   Google Scholar
• Garnock-Jones KP. Ecallantide: in acute hereditary angioedema. Drugs70(11), 1423–1431 (2010).
   PubMedGoogle Scholar
• Stolz LE, Horn PT. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema. Drugs Today (Barc.).46(8), 547–555 (2010).
   PubMedGoogle Scholar
• Firazyr® (icatibant), package insert. Shire Orphan Therapies, Inc., Lexington, MA, USA (2011).
   Google Scholar
• Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N. Engl. J. Med.363(6), 532–541 (2010).
   PubMed Web of Science ®Google Scholar
• Ley AC, Markland W, Ladner RC. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein. Mol. Divers2(1–2), 119–124 (1996).
   PubMed Web of Science ®Google Scholar
• Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry35(24), 8058–8067 (1996).
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Qazi M. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev. Clin. Immunol.6(1), 29–39 (2010).
   PubMed Web of Science ®Google Scholar
• Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Exp. Opin. Investig. Drugs15(9), 1077–1090 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol.120(2), 416–422 (2007).
   PubMed Web of Science ®Google Scholar
• Cicardi M, Levy RJ, Mcneil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N. Engl. J. Med.363(6), 523–531 (2010).
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, Mcneil DL et al. EDEMA4: a Phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann. Allergy Asthma Immunol.104(6), 523–529 (2010).
   PubMed Web of Science ®Google Scholar
• Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual. Life Res.18(7), 929–939 (2009).
   PubMedGoogle Scholar
• Riedl M, Campion M, Horn PT, Pullman WE. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann. Allergy Asthma Immunol.105(6), 430–436.e432 (2010).
   PubMedGoogle Scholar
• Sheffer AL, Campion M, Levy RJ, Li HH, Horn PT, Pullman WE. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, Phase 3 studies. J. Allergy Clin. Immunol.128(1), 153–159.e4 (2011).
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy63(6), 751–757 (2008).
   PubMed Web of Science ®Google Scholar
• Sampson HA, Munoz-Furlong A, Campbell RL et al. Second symposium on the definition and management of anaphylaxis: summary report – Second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposium. J. Allergy Clin. Immunol.117(2), 391–397 (2006).
   PubMedGoogle Scholar
• Zuraw BL, Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc.30(5), 487–492 (2009).
   PubMedGoogle Scholar
• Krassilnikova S, Craig ET, Craig TJ. Summary of the International Multicenter Prospective Angioedema C1-Inhibitor Trials 1 and 2 (IMPACT1 and 2). Expert Rev. Clin. Immunol.6(3), 327–334 (2010).
   PubMed Web of Science ®Google Scholar
• Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J. Allergy Clin. Immunol.126(4), 821–827 e814 (2010).
   PubMed Web of Science ®Google Scholar
• Davis B, Bernstein JA. Conestat α for the treatment of angioedema attacks. Ther. Clin. Risk Manag.7, 265–273 (2011).
   PubMed Web of Science ®Google Scholar